Search

Your search keyword '"Hieke K"' showing total 124 results
Start Over Author "Hieke K"
124 results on '"Hieke K"'

10. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

Author

Brown, B, Diamantopoulos, A, Bernier, J, Schöffski, P, Hieke, K, Mantovani, L, Launois, R, Griebsch, I, Robinson, P, Brown B, Diamantopoulos A, Bernier J, Schöffski P, Hieke K, Mantovani L, Launois R, Griebsch I, Robinson PP, Brown, B, Diamantopoulos, A, Bernier, J, Schöffski, P, Hieke, K, Mantovani, L, Launois, R, Griebsch, I, Robinson, P, Brown B, Diamantopoulos A, Bernier J, Schöffski P, Hieke K, Mantovani L, Launois R, Griebsch I, and Robinson PP

Abstract

Objectives: A phase III randomized trial that compared the combination of cetuximab and radiotherapy to radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck provided a platform for a comprehensive economic evaluation. The study was conducted to estimate the cost-effectiveness of cetuximab in combination with radiotherapy compared to radiotherapy alone, for the treatment of locally advanced head and neck cancer in patients for whom chemoradiotherapy is inappropriate or intolerable. Methods: Separate economic analyses were conducted for Belgium, France, Italy, Switzerland, and the United Kingdom. The economic model was based on individual patient data extracted from an international phase III trial. Country-specific costs of care from official sources were applied in each analysis. Clinical expert panels supplemented resource use estimates from the phase III trial and validated assumptions used to extrapolate costs and health outcomes beyond the follow-up of the phase III trial. Results: In the base-case analysis, the incremental cost per quality-adjusted life-year for patients receiving radiotherapy in combination with cetuximab compared to radiotherapy alone among all countries was in the range of €7538 to €10,836. Sensitivity analysis showed the results to be robust. Conclusion: This cost-effectiveness analysis indicated that the addition of cetuximab to high-dose radiotherapy offers a good value-for-money alternative to radiotherapy alone in the treatment of locally advanced head and neck cancer in five European countries. © 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Published
2008

11. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy

Author

Bandello, Francesco Maria, Augustin, A, Sahel, Ja, Benhaddi, H, Negrini, C, Hieke, K, Berdeaux, Gh, Collaborators: Sahel J, MICMAC Study G. r. o. u. p., Chaine, G, Weber, M, Quentel, G, Cohen, Sy, Mauget Faysse, M, Brasseur, G, Nicole, C, Korobelnik, Jf, Benchaboune, M, Charlin, Jf, Augustin, Weinhold, Kaut, Hyppa, Jurgeit, Incorvaia, Carlo, Bandello, F, Menchini, U, Boscia, F, Malerba, Setaccioli, Varano, M, Schiano, Bandello, F, Augustin, A, Sahel, Ja, Benhaddi, H, Negrini, C, Hieke, K, and Berdeaux, Gh

Subjects
Male, medicine.medical_specialty, Visual acuity, genetic structures, Cross-sectional study, Visual Acuity, Severity of Illness Index, Macular Degeneration, Cost of Illness, Germany, Severity of illness, Humans, Medicine, Pharmacology (medical), Aged, Analysis of Variance, business.industry, Age-related macular degeneration, costs of ARMD, Data Collection, Public health, Health Care Costs, Macular degeneration, medicine.disease, Home Care Services, Verteporfin, eye diseases, Cross-Sectional Studies, Italy, Fees and Charges, Optometry, Female, France, Health Expenditures, Geriatrics and Gerontology, medicine.symptom, business, Developed country, medicine.drug, Retinopathy
Abstract

Introduction: Exudative ('wet') age-related macular degeneration (ARMD) is the major cause of blindness in Western developed countries. Treatments aimed at preserving vision are already available and new compounds are under development. Micro-economics information will be pivotal to justifying forthcoming investment. Objective: This study sought to investigate the costs of exudative ARMD in patients who were actively treated at ophthalmology referral centres in three European countries: France, Germany and Italy. Method: This cross-sectional observational study was conducted in France, Germany and Italy in 2004. The following data were collected: ARMD description, visual acuity (VA), and the medical and non-medical resources used for ARMD in the preceding year. The economic perspective was that of society. ANOVA for cost variables estimated the impact of ARMD per eye, adjusted for sex and age. Both hospital and ambulatory eye centres were included. Patients with exudative ARMD were stratified into four levels of severity using VA thresholds of 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). The main outcome measure was medical and non-medical costs. Results: 360 patients were included (females 60%; mean age 77 years; mean interval since diagnosis 2.3 years). The two groups with the greatest difference in severity of VA loss consisted of BE >= 20/40, WE >= 20/200 (27.2% of patients) and BE

Published
2008

13. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use

Author

Herold, M., Stefano Sacchi, and Hieke, K.

Subjects
relapse, non-Hodgkin's lymphoma, Male, Salvage Therapy, cost of treatment, Data Collection, Developed Countries, Lymphoma, Non-Hodgkin, Middle Aged, Global Health, Drug Costs, Resource Allocation, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Costs and Cost Analysis, Humans, Female
Abstract

Few economic data exist on the treatment of indolent non-Hodgkin's lymphoma (NHL) and there are none in the published literature concerning relapsed disease. This international analysis (Canada, Germany, Italy) was established to estimate the overall direct cost of treating patients with relapsed indolent NHL and determine the main cost components of treatment.Telephone interviews were used to identify the most commonly used treatment regimens in each country. CHOP, CVP and fludarabine were chosen for economic analysis, which was based on retrospective data from 424 patients.Overall treatment costs for a course of six cycles varied more than 5-fold, from 3,445 to 17,940 Euros between regimens and countries. The treatment setting had a major impact on costs, with in-patient costs being up to three times greater than the equivalent out-patient values. Drug administration costs comprised 46-60% of the overall treatment costs in the in-patient setting. Adverse event management was the major cost component for out-patient CHOP and CVP therapy (52-75%), and a significant proportion (24-40%) of in-patient costs for these regimens. Drug acquisition accounted for less than half of treatment costs for most of the regimens analyzed.This study shows that not simply drug acquisition costs, but the costs of drug administration, particularly in the in-patient setting, and adverse event management are major contributors to the overall treatment costs for relapsed indolent NHL.

Published
2002

38. Hydride vapour phase epitaxy for nanostructures

Author

Rodrı́guez Messmer, E, primary, Lourdudoss, S, additional, Ahopelto, J, additional, Lipsanen, H, additional, Hieke, K, additional, Wesström, J.-O, additional, Reithmaier, J.P, additional, Kerkel, K, additional, Forchel, A, additional, Seifert, W, additional, Carlsson, N, additional, and Samuelson, L, additional

Published
1998
Full Text
View/download PDF

50. Exciton transfer in quantum well structures

Author

Goede, O., primary, Heimbrodt, W., additional, Hieke, K., additional, Gumlich, H.-E., additional, Pier, Th., additional, Lunn, B., additional, Ashenford, D.E., additional, Jackson, S., additional, and Nicholls, J.E., additional

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results